Skip to main content
. 2018 Sep 21;7(10):5015–5026. doi: 10.1002/cam4.1776

Table 4.

OS and CSS between different histology of cancer with or without radiotherapy after PSMa

Histology Treatment n OS (95% CI)b mo P c CSS (95% CI)b mo P c
AD No RT 5429 11.6 (11.2‐12.0) 0.423 12.6 (12.1‐13.0) 0.205
RT 5429 11.0 (10.6‐11.4) 11.8 (11.4‐12.2)
SQC No RT 2397 7.6 (7.1‐8.1) <0.001 8.6 (8.0‐9.1) <0.001
RT 2397 9.6 (9.1‐10.1) 10.7 (10.1‐11.3)
Other No RT 448 9.8 (8.4‐11.2) 0.061 10.8 (9.3‐12.4) 0.119
RT 448 10.6 (9.4‐11.8) 11.2 (9.9‐12.6)
LCC No RT 222 6.3 (5.0‐7.5) 0.041 6.6 (5.3‐7.9) 0.044
RT 222 8.2 (6.6‐9.8) 8.6 (6.9‐10.3)
Unspecified No RT 1746 6.8 (6.3‐7.4) <0.001 7.7 (7.0‐8.3) <0.001
RT 1746 8.9 (8.3‐9.5) 9.6 (8.9‐10.3)
All NSCLC No RT 14 066 10.8 (10.5‐11.0) 0.857 11.8 (11.6‐12.1) 0.080
RT 14 066 10.4 (10.1‐10.6) 11.1 (10.9‐11.4)

PSM, propensity score matching; n, number of cases/controls; RT, radiotherapy; OS, overall survival; CSS, cancer‐specific survival; CI, confidence interval; AD, adenocarcinoma; SQC, squamous cell carcinoma; Other, other specified carcinoma; LCC, large cell carcinoma; Unspecified, unspecified malignant neoplasm; NSCLC, non‐small cell lung cancer.

PSM were done in each subgroup using variables including: age, gender, race, marital, grade, T stage, N stage, chemotherapy, surgery, radiotherapy, and metastatic sites of bone, brain, liver, and lung.

Derived from Kaplan‐Meier survival analysis.

Derived from log‐rank test statistics.